MMMaria Perez Morales

Maria Perez Morales

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maria Perez Morales has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Benralizumab achieves sustained remission and glucocorticoid sparing in patients with eosinophilic granulomatosis with polyangiitis and asthma: a Spanish multicentre real-world cohort study

    by A. Padilla-Galo, C. Martínez-Rivera, A. Trisán-Alonso, A. Gómez-Bastero, Á. Martínez-Mesa, C. Pinedo-Sierra, J. C. Miralles-López, F. Casas-Maldonado, E. Arismendi, M. Pérez-Morales, et al.

  • Open Access

    Real-life cost-effectiveness of benralizumab in patients with severe asthma

    by A. Padilla-Galo, A. J. García-Ruiz, R. Ch. Levy Abitbol, C. Olveira, F. Rivas-Ruiz, N. García-Agua Soler, M. Pérez Morales, B. Valencia Azcona, B. Tortajada-Goitia, I. Moya-Carmona, et al.

    Background: Availability of clinically effective and cost-effective treatments for severe asthma would be beneficial to patients and national healthcare systems. The aim of this study was to evaluate clinical outcomes and healthcare expenditure after incorporating benralizumab into the standard treatment of refractory eosinophilic asthma. Methods: This was a cross-sectional multicentre study of consecutive patients with refractory eosinophilic asthma who received treatment with benralizumab during at least 12 months. Patient follow-up was performed in specialised severe asthma units. The main effectiveness parameters measured were: the avoidance of one asthma exacerbation, a 3-point increase in the asthma control test (ACT) score, and the difference in utility scores (health-related quality of life) between a 1-year baseline treatment and 1-year benralizumab treatment. The health economic evaluation included direct costs and incremental cost-effectiveness ratios (ICERs). Results: After 1 year of treatment with benralizumab, patients with refractory eosinophilic asthma showed an improvement in all the effectiveness parameters analysed: improvement of asthma control and lung function, and decrease in the number of exacerbations, oral corticosteroid (both as corticosteroid courses and maintenance therapy), and inhaled corticosteroid use. The total annual cost per patient for the baseline and benralizumab treatment periods were €11,544 and €14,043, respectively, reflecting an increase in costs due to the price of the biological agent but a decrease in costs for the remaining parameters. The ICER was €602 per avoided exacerbation and €983.86 for every 3-point increase in the ACT score. Conclusions: All the pharmacoeconomic parameters analysed show that treatment with benralizumab is a cost-effective option as an add-on therapy in patients with refractory eosinophilic asthma.


  • Concordance between pulmonologist performed rapid on-site evaluation (ROSE) and pathological diagnosis in EBUS-TBNA samples

    by Maria Perez Morales, María Morales González, Cayo Javier García Polo, Enrique José González-Moya Rodriguez De Mondelo, Mercedes Merino Sánchez

    Introduction: Sometimes it’s not easy have a pathologist to perform ROSE during an EBUS-TBNA procedure. Our objective was to analyze the concordance between ROSE performed by pulmonologists and the definitive pathological diagnosis. Methods: Retrospective analysis of EBUS-TBNA performed in our center, from february 2016 to september 2019, in which ROSE was performed by a pulmonologist through a fresh staining with panoptic rapid immersion technique. Results were reported as valid/suggestive, valid/non-suggestive and non-valid/non-suggestive, depending on lymphocytes and atypical cells presence. A comparison with the definitive pathological diagnosis is done, in all cases performed and those in which a malignancy diagnosis was obtained. Results: 453 EBUS-TBNA procedures analyzed in the study period, 198 met study criteria. Average age 64.08, 155 male sex. 437 punctures of hiliomediastinal lymph nodes (LN) were performed, average 3.66 punctures per LN. Punctured LN stations were 7 (n=140), 4R (n=104), 4L (n=58), 11L (n=34), 2R (n=31), 11R (n=29), 10R (n=19), 10L (n=8), 2L (n=8), 8 (n=4) and 3p (n=2). Valid/suggestive result was obtained in 104 patients (52.3%), valid/non-suggestive in 81 (40.9%) and non-valid /non-suggestive in 13 (6.6%). The overall concordance was considered as a moderate degree (kappa index 0.494). Concordance related to malignancy ROSE results (valid/suggestive) is considered as a high degree relation (kappa index 0.952), with sensitivity 98.9%, specificity 92.3% and NPV 92.3%. Conclusions: ROSE of EBUS-TBNA mediastinal LN cytological samples performed by pulmonologists show a high concordance in case of malignancy results.


  • Open Access

    Real-life experience with benralizumab during 6 months

    by A. Padilla-Galo, Rch Levy-Abitbol, C. Olveira, B. Valencia Azcona, M. Pérez Morales, F. Rivas-Ruiz, B. Tortajada-Goitia, I. Moya-Carmona, A. Levy-Naon

    Background: Benralizumab is a monoclonal antibody that binds to the human interleukin-5 (IL-5) receptor (IL-5R), thereby preventing IL-5 from binding to its receptor and inhibiting differentiation and maturation of eosinophils in the bone marrow. Because of its recent marketing approval, sufficient real-life evidence is lacking to confirm the efficacy and safety data from clinical trials. The purpose of this study was to evaluate the efficacy and safety of benralizumab for the treatment of severe refractory eosinophilic asthma in a real-world cohort of patients.Methods: This was a cross-sectional multicentre study of consecutive patients with severe refractory eosinophilic asthma who received treatment with benralizumab during at least 6 months. Patient follow-up was performed in specialised severe asthma units.Results: A total of 42 patients were enrolled and treated with benralizumab. Asthma control, as measured by the asthma control test (ACT), improved in all patients both at 3 months of treatment compared with baseline (13.9 ± 4 vs 20.1 ± 3.7,p < 0.001) and at 6 months of treatment compared with the results obtained at 3 months (20.1 ± 3.7 vs 21 ± 2.7,p = 0.037). Similarly, the number of emergency department visits decreased both at 3 months compared with baseline (1 [IR:0.7] vs 0 [IR:0.75],p < 0.001) and at 6 months compared with the results at 3 months (0 [IR:0.75] vs 0 [IR:0],p = 0.012). Reductions in the number of oral corticosteroid cycles, percentage of corticosteroid-dependent patients, and mean daily dose of oral or inhaled corticosteroid were also evidenced. Finally, mean lung function improvement was 291 mL (p < 0.001), and FEV1% improved both at 3 months compared with baseline (64.4 ± 9.3 vs 73.1 ± 9.1,p < 0.001) and at 6 months compared to 3 months (73.1 ± 9.1 vs 76.1 ± 12,p = 0.002). Side effects were mild and did not lead to treatment discontinuation.Conclusions: This study confirms the efficacy and safety of benralizumab in a real-life setting with improved asthma control and lung function, and a reduced oral and inhaled corticosteroid use as well as fewer emergency department visits. In addition to a rapid initial improvement, it appears that patients continue to improve during the first 6 months of treatment.


  • Characteristics of patients treated with nicotine replacement therapy (NRT) prescribed during hospitalization

    by Maria Perez Morales, Carolina España Domínguez, María Morales González, Isabel Muñoz Ramírez, Mercedes Merino Sánchez, Aurelio Arnedillo Muñoz

    Introduction: The aim of the study was to analyze the characteristics of patients and prescribers of treatment with NRT, after the implementation of a treatment program in our hospital for admitted smokers. Methods: A retrospective descriptive analysis of smokers treated during the period of hospitalization with NRT between 2013-2017 in our hospital, evaluating the diagnosis on admission, comorbidities, services involved, and effectiveness of the treatment at month, 6 months and 1 year after hospital discharge. Results: We obtained valid data in 88 patients, 53 (60.2%) males with mean age of 60.4 ± 12.06 years. The cumulative index of average tobacco was 52.25 ± 27.8 and the mean stay was 10.97 ± 9.28 days. The most frequent diagnosis on admission were COPD in 25% of cases, lung cancer in 10.2%, hemoptysis in 6.8%, pneumonia in 6.8%, stroke, digestive pathology and non-pulmonary cancer in 4.5% each one and finally ischemic heart disease in 3.4%. The comorbidities most frequently found were COPD (43.2%), arterial hypertension (35.2%), dyslipidemia (30.7%), depression (29.5%), diabetes (27.3%), alcoholism (25 %), anxiety (21.6%), drugs addiction (14.8%), lung cancer (13.6%), ischemic heart disease (12.5%) and stroke (10.2%). The majority of the patients were admitted in the Pneumology (54.5%) and Internal Medicine departments (23.9%). One month after discharge, 50% of them had quit smoking, at 6 months 40.9% and after one year 43.2%. Only 29.5% of treated patients were followed in a tobacco cessation unit after discharge. Conclusions: The follow-up after discharge in specialized units of tobacco cessation is very low, yet the efficacy of the treatment per year was high.